• LAST PRICE
    0.0000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 0.0000
  • Day Range
    ---
  • 52 Week Range
    Low 0.0000
    ---
    High 0.0001
  • Volume
    ---

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
Table Data Not Available
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTNGNQ
Tengion Inc
40.0
0.0x
---
United StatesGTHR
GeneThera Inc
40.0
0.0x
---
United StatesHDVY
Health Discovery Corp
4.1K
0.0x
---
United StatesVRCI
Verde Science Inc
20.0
0.0x
---
United StatesPFND
Pathfinder Cell Therapy Inc
670.0
0.0x
---
United StatesEAPH
Easton Pharmaceuticals Inc
1.3K
0.0x
---
As of 2024-04-26

Company Information

Tengion, Inc. is a regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ.  The Company, by using its Organ Regeneration Platform, it creates neo-organs using patient’s own cells.  The Company, based on its clinical and preclinical experience is leveraging its Organ Regeneration Platform to develop Neo-Kidney Augment for patients with advanced chronic kidney disease and Neo-Urinary Conduit for bladder cancer patients who are in need of a urinary diversion. The Company’s product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.

Contact Information

Headquarters
Suite G, 3929 Westpoint Blvd.WINSTON-SALEM, NC, United States 27103
Phone
336-722-5855
Fax
302-655-5049

Executives

No data available

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$40.00
Revenue (TTM)
$0.00
Shares Outstanding
40.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.41
Book Value
$-2.47
P/E Ratio
0.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.